Literature DB >> 25691679

Disparities in castration-resistant prostate cancer trials.

Daniel E Spratt1, Joseph R Osborne2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25691679      PMCID： PMC4372848          DOI： 10.1200/JCO.2014.58.1751

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

Review 1.  New developments in the management of prostate cancer.

Authors:  Philip W Kantoff; James L Mohler
Journal:  J Natl Compr Canc Netw       Date:  2013-05       Impact factor: 11.908

2.  Project data sphere to make cancer clinical trial data publicly available.

Authors:  Karyn Hede
Journal:  J Natl Cancer Inst       Date:  2013-07-31       Impact factor: 13.506

3.  Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.

Authors:  Ernest T Hawk; Elizabeth B Habermann; Jean G Ford; Jennifer A Wenzel; Julie R Brahmer; Moon S Chen; Lovell A Jones; Thelma C Hurd; Lisa M Rogers; Lynne H Nguyen; Jasjit S Ahluwalia; Mona Fouad; Selwyn M Vickers
Journal:  Cancer       Date:  2014-04-01       Impact factor: 6.860

4.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

5.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

6.  Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.

Authors:  Aisha T Langford; Ken Resnicow; Eileen P Dimond; Andrea M Denicoff; Diane St Germain; Worta McCaskill-Stevens; Rebecca A Enos; Angela Carrigan; Kathy Wilkinson; Ronald S Go
Journal:  Cancer       Date:  2013-12-10       Impact factor: 6.860

7.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 8.  A systematic review of the factors influencing African Americans' participation in cancer clinical trials.

Authors:  Desiree Rivers; Euna M August; Ivana Sehovic; B Lee Green; Gwendolyn P Quinn
Journal:  Contemp Clin Trials       Date:  2013-04-01       Impact factor: 2.226

9.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

10.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245
View more
  18 in total

1.  Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.

Authors:  Emily M Rencsok; Latifa A Bazzi; Rana R McKay; Franklin W Huang; Adam Friedant; Jake Vinson; Samuel Peisch; Jelani C Zarif; Stacey Simmons; Kelly Hawthorne; Paul Villanti; Philip W Kantoff; Elisabeth Heath; Daniel J George; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-06-05       Impact factor: 4.254

2.  Racial/Ethnic Disparities in Genomic Sequencing.

Authors:  Daniel E Spratt; Tiffany Chan; Levi Waldron; Corey Speers; Felix Y Feng; Olorunseun O Ogunwobi; Joseph R Osborne
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

3.  Building Toward Antiracist Cancer Research and Practice: The Case of Precision Medicine.

Authors:  Jacob N Stein; Marjory Charlot; Samuel Cykert
Journal:  JCO Oncol Pract       Date:  2021-05

4.  Reporting of Racial Health Disparities Research: Are We Making Progress?

Authors:  Randy A Vince; Nicholas W Eyrich; Brandon A Mahal; Kristian Stensland; Edward M Schaeffer; Daniel E Spratt
Journal:  J Clin Oncol       Date:  2021-10-25       Impact factor: 44.544

Review 5.  Racial disparities in prostate cancer among black men: epidemiology and outcomes.

Authors:  Daniel J George; Lorelei A Mucci; Ilkania M Chowdhury-Paulino; Caroline Ericsson; Randy Vince; Daniel E Spratt
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-09-02       Impact factor: 5.455

6.  Racial Differences in Genomic Profiling of Prostate Cancer.

Authors:  Brandon A Mahal; Mohammed Alshalalfa; Kevin H Kensler; Ilkania Chowdhury-Paulino; Philip Kantoff; Lorelei A Mucci; Edward M Schaeffer; Daniel Spratt; Kosj Yamoah; Paul L Nguyen; Timothy R Rebbeck
Journal:  N Engl J Med       Date:  2020-09-10       Impact factor: 176.079

7.  Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.

Authors:  Che-Kai Tsao; John Sfakianos; Bobby Liaw; Kiev Gimpel-Tetra; Margaret Kemeny; Linda Bulone; Mohammad Shahin; William Kyu Oh; Matthew David Galsky
Journal:  Oncologist       Date:  2016-10-14

8.  NCI-Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center.

Authors:  Daniel J Kim; Dan Otap; Nora Ruel; Naveen Gupta; Naveed Khan; Tanya Dorff
Journal:  J Clin Med       Date:  2020-06-24       Impact factor: 4.241

9.  A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy.

Authors:  Celia P Kaplan; Adam Siegel; Yan Leykin; Nynikka R Palmer; Hala Borno; Jessica Bielenberg; Jennifer Livaudais-Toman; Charles Ryan; Eric J Small
Journal:  Contemp Clin Trials Commun       Date:  2018-08-15

10.  Comprehensive signature analysis of drug metabolism differences in the White, Black and Asian prostate cancer patients.

Authors:  Yang Liu; Jia-Wei Zhou; Cun-Dong Liu; Jian-Kun Yang; De-Ying Liao; Zhi-Jian Liang; Xiao Xie; Qi-Zhao Zhou; Kang-Yi Xue; Wen-Bing Guo; Ming Xia; Jun-Hao Zhou; Ji-Ming Bao; Cheng Yang; Hai-Feng Duan; Hong-Yi Wang; Zhi-Peng Huang; Shan-Chao Zhao; Ming-Kun Chen
Journal:  Aging (Albany NY)       Date:  2021-06-18       Impact factor: 5.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.